2025年迪高替尼软膏最新价格是多少钱一盒？

Digotinib ointment is an innovative topical JAK inhibitor that belongs to the Janus kinase (JAK) inhibitor family. By inhibiting the activation of the JAK-stat pathway, it can regulate the immune system in a targeted manner, thus playing a key role in the treatment of chronic inflammatory skin diseases such as atopic dermatitis. The 0.25% concentration (5g/stick, 10-pack) is about US$96 per box, and the 0.5% concentration (5g/stick, 10-pack) is about US$130 per box. The drug has been approved for marketing in many countries including Japan, but has not yet been introduced in mainland China. Patients need to be fully prepared before use, including skin assessment, allergy testing, etc.

How much is the latest price of a box of Digotinib ointment in 2025

The market price in 2025 will be basically the same as in previous years. The pricing differences of products with different concentrations and specifications are mainly due to the content of drug ingredients and treatment intensity.

0.25% concentration specification price

The price of 5g/tube 0.25% concentration product in a box of 10 tubes remains at around US$96. This specification is suitable for patients with mild to moderate symptoms, especially for children.

Price of 0.5% concentration specification

For 5g/tube of 0.5% concentration product, the price of a box of 10 units is approximately US$130. The higher concentration version targets moderate to severe symptoms in adults and has a more significant therapeutic effect.

The price may fluctuate by US$5-10 due to purchase channels, transportation costs and exchange rate fluctuations. It is recommended to obtain real-time quotes through formal medical channels.

Global marketing status of Digotinib Ointment

Digotinib Ointment has been approved for marketing in many countries and regions, but the approved indications and specifications may differ in various regions.

Launch status in Asia

Japan, as the first country to approve it, provides two concentrations of 0.25% and 0.5%. Countries such as South Korea and Singapore have also approved marketing, but the specifications may be slightly different.

Approval progress in Europe and the United States

The US FDA and EU EMA are still under review, and clinical trial data shows that it is equally effective for European and American populations.

Mainland China has not yet been included in the approval schedule, and patients need to obtain products from listed countries through cross-border channels.

Preparation for the administration of Digotinib Ointment

Standardized early preparation is beneficial to the effectiveness of the drug and requires the cooperation of patients and medical staff.

Skin condition assessment

Before use, a professional physician must evaluate the degree and scope of skin damage to determine the appropriate drug concentration and dosage. Co-infections must be controlled first.

Allergy test

Before first use, an allergy test should be conducted on a small area of ​​skin, and no adverse reactions should be observed for 24-48 hours before use on a large area.

Medication education

Medical staff need to explain in detail the correct application technique, frequency of use and possible adverse reactions to ensure that patients master the correct medication method.

It is recommended to establish a medication diary to record the time, dosage and skin reaction of each medication for reference by the doctor during follow-up visits.